GO
Loading...

Medicine

More

  • TRENTON, N.J.— Drugmaker Bristol-Myers Squibb Co. said Thursday that an experimental combination of two hepatitis C drugs— its daclatasvir and Gilead Sciences Inc.' s blockbuster drug Sovaldi— cured hepatitis C in just 12 weeks in nearly all the patients, who also are infected with the HIV virus. David Wyles, an associate professor at University of...

  • Heat blamed for spray vaccine's failure against swine flu Thursday, 26 Feb 2015 | 12:53 PM ET

    ATLANTA— The makers of the nasal spray version of the flu vaccine say now they know why it has failed to protect young U.S. children against swine flu— fragile doses got too warm. The AstraZeneca FluMist vaccine works well for most flu strains, but small studies found it didn't work very well against the swine flu bug that first emerged in 2009. Swine flu has returned...

  • NEW YORK— You may think you're immune to transparent sales pitches like "Do you want fries with that?" But the tactics restaurants use to nudge you into spending a little extra may be subtler than you realize. Greg Rapp, a menu consultant in California, says he advises restaurants and fast-food chains to leave those off when listing prices on a menu.

  • US panel: Use new meningitis vaccines only for outbreaks Thursday, 26 Feb 2015 | 12:11 PM ET

    ATLANTA— A federal panel on Thursday recommended that two new meningitis vaccines only be used for rare outbreaks, resisting tearful pleas to give it routinely to teens and college students. So the Advisory Committee on Immunization Practices declined to recommend routine shots for all adolescents and college students. One woman, Patti Wukovits from New...

  • Feb 26- Diagnostics company Corgenix Medical Corp said on Thursday U.S. health regulators had approved its rapid Ebola test for emergency use, in response to the world's worst outbreak of the virus that killed more than 10,000 so far. The company's ReEBOV Antigen Rapid Test, which involves putting a drop of blood on a paper strip and waiting for at least 15 minutes...

  • FDA approves Corgenix's Ebola test for emergency use Thursday, 26 Feb 2015 | 9:34 AM ET

    Feb 26- Corgenix Medical Corp said on Thursday the U.S. Food and Drug Administration approved its Ebola test for emergency use. The company's so-called ReEBOV Antigen Rapid Test involves putting a drop of blood on a small paper strip and waiting for 15-25 minutes for a reaction. The test is able to correctly identify about 92 percent of Ebola-infected patients...

  • Bayer is 'focusing on life sciences'  Thursday, 26 Feb 2015 | 6:00 AM ET

    Marijn Dekkers, CEO of Bayer, talks about the company's plans to separate themselves from their material science unit, saying they will focus on life sciences businesses going forward.

  • Feb 26- Sanofi's new Toujeo diabetes drug has won U.S. regulatory approval but with wording on its label that analysts say could make marketing difficult. Sanofi shares were 1 percent lower at 88.20 euros by 1029 GMT. Sanofi bought some time with a patent infringement lawsuit filed last year against Eli Lilly and Co to keep a cheaper Lantus generic off the market...

  • SYDNEY, Feb 26- Australian Prime Minister Tony Abbott backed plans on Thursday to introduce country-of-origin labelling in the wake of a hepatitis A outbreak, potentially risking contravention of World Trade Organization rules. Australia was among plaintiffs against the United States after it introduced its own stronger country-of-origin labelling...

  • Tandem Diabetes reports 4Q loss Tuesday, 24 Feb 2015 | 6:39 PM ET

    SAN DIEGO _ Tandem Diabetes Care Inc. on Tuesday reported a loss of $18.5 million in its fourth quarter. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 81 cents per share. Analysts expected $17.2 million, according to Zacks.

  • SEATTLE— For the first time, a study shows that a drug used to treat HIV infection also can help prevent it when taken before and after risky sex by gay men. The study, done in France and Canada, is the first to test "on demand" use of Truvada, a pill combining two AIDS drugs, by people planning to have risky sex. He is an AIDS specialist at Columbia University in New York and...

  • Feb 24- An experimental therapeutic vaccine from Danish drugmaker Bavarian Nordic helped significantly extend survival in patients with advanced prostate cancer, according to results of a small early-stage trial conducted by the U.S. National Cancer Institute. Patients were treated with the company's Prostvac vaccine, in addition to escalating doses of...

  • LONDON, Feb 24- Sierra Leone could see growth rebound to double digits over the next 3-5 years as it emerges from the Ebola crisis and plans to tap its diaspora to raise funds for development, its foreign minister said. The west African country's economy was ravaged by the recent year-long outbreak of the Ebola virus that killed more than 9,000 people across...

  • The Biomedical Advanced Research and Development Authority has told the company that its anti-Ebola treatments should be efficient as Mapp Biopharmaceutical's ZMapp. The number of new cases has plummeted but officials have said much work still needs to be done before the virus is snuffed out in Liberia, Guinea and Sierra Leone, the three worst affected...

  • Watchdog group seeks FDA ban of antifungal tablets Tuesday, 24 Feb 2015 | 10:08 AM ET

    Public Citizen filed a petition Tuesday asking the FDA to ban ketoconazole tablets, which are used against hard-to-treat fungal infections. In July 2013 the FDA restricted ketoconazole's use to infections that do not respond to other drugs. Those findings were delivered at an agency workshop in January 2013, six months before the FDA decided to restrict the...

  • Feb 24- CymaBay Therapeutics Inc said its experimental lead pill met the main goal of reducing episodes of gout in a mid-stage study. Described as a painful and common form of inflammatory arthritis, gout affects nearly 8.3 million Americans, according to the U.S. Centers for Disease Control and Prevention, citing data. The compound has been available in the...

  • CymaBay's gout drug meets main goal in mid-stage study Tuesday, 24 Feb 2015 | 6:24 AM ET

    Feb 24- CymaBay Therapeutics Inc said its experimental lead drug met the main goal of reducing episodes of gout in a mid-stage study. The company said the drug, arhalofenate, was shown to be safe and well tolerated. Gout is a condition affecting joints and muscles when the body acts against a build-up of uric acid in the blood.

  • Merck grants free license for pediatric HIV drug Tuesday, 24 Feb 2015 | 3:02 AM ET

    TRENTON, N.J.— Drugmaker Merck& Co. has granted a free license allowing one of its HIV medicines to be made and sold inexpensively for use in young children in poor countries hard hit by the AIDS virus. The group, backed by the United Nations, works with brand-name drugmakers to find ways to make their HIV medicines still covered by patents available in developing...

  • LOS ANGELES— California health officials' latest update shows no new measles cases for the first time since the Disneyland outbreak began last year— an encouraging sign that infections may be waning. The Department of Public Health said Monday that the number of measles cases stands at 123, the same total as Friday. Another two dozen measles cases traced to...

  • Feb 23- The U.S. Food and Drug Administration on Monday approved Novartis AG's drug to treat patients who have relapsed after earlier therapies for multiple myeloma, an aggressive blood cancer, even though an advisory panel in November recommended against approval. Farydak was approved for use in combination with Takeda Pharmaceutical Co Ltd's Velcade and...